Why the study?
What are the real-world safety findings and risks for major bleeding in patients treated with direct oral anticoagulants based on postmarketing surveillance studies?
What are the real-world safety findings and risks for major bleeding in patients treated with direct oral anticoagulants based on postmarketing surveillance studies?
This review summarizes postmarketing surveillance data to provide real-world evidence on the safety and major bleeding risks of direct oral anticoagulants in a broader patient population than included in phase 3 trials.
No takes yet. Share an insight, caveat, or question.
May warrant closer bleeding surveillance beyond trial populations; leaves open need for prospective validation.
Villines et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: